Inventiva Announces 2025 Financial Results and Business Update

Inventiva, a biopharmaceutical company, disclosed its financial results for 2025. The company reported revenues of €4.5 million for the year. Cash reserves, including cash equivalents and short-term deposits, totaled €230.9 million by year's end. In 2025, Inventiva executed a U.S. public offering, securing approximately €149 million. This leaves a cash runway anticipated until early 2027.

There were notable developments, including the sale of odiparcil with potential future payments, and the forthcoming NATiV3 Phase 3 trial results in late 2026. R&D expenses declined by 4% due to strategic pipeline adjustments. Financing activities generated €241.3 million, while operations utilized €104.9 million in cash. A conference call is scheduled for March 31, 2026, to discuss these updates.